222 related articles for article (PubMed ID: 26324045)
1. Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
Latham CF; La J; Tinetti RN; Chalmers DK; Tachedjian G
Curr Top Med Chem; 2016; 16(10):1135-53. PubMed ID: 26324045
[TBL] [Abstract][Full Text] [Related]
2. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments.
Gill MSA; Hassan SS; Ahemad N
Eur J Med Chem; 2019 Oct; 179():423-448. PubMed ID: 31265935
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.
Tarrago-Litvak L; Andreola ML; Fournier M; Nevinsky GA; Parissi V; de Soultrait VR; Litvak S
Curr Pharm Des; 2002; 8(8):595-614. PubMed ID: 11945161
[TBL] [Abstract][Full Text] [Related]
4. Search for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challenges.
Kharkwal H; Kumar BK; Murugesan S; Singhvi G; Avasthi P; Goyal A; Jamalis J; Chander S
Future Med Chem; 2021 Feb; 13(3):269-286. PubMed ID: 33399497
[TBL] [Abstract][Full Text] [Related]
5. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Gago F
Antiviral Res; 2006 Sep; 71(2-3):260-7. PubMed ID: 16872687
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase.
Andréola ML
Curr Pharm Des; 2009; 15(21):2508-19. PubMed ID: 19601847
[TBL] [Abstract][Full Text] [Related]
7. Beauvericin and enniatins H, I and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase.
Shin CG; An DG; Song HH; Lee C
J Antibiot (Tokyo); 2009 Dec; 62(12):687-90. PubMed ID: 19893585
[TBL] [Abstract][Full Text] [Related]
8. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase.
Wang Z; Tang J; Salomon CE; Dreis CD; Vince R
Bioorg Med Chem; 2010 Jun; 18(12):4202-11. PubMed ID: 20576573
[TBL] [Abstract][Full Text] [Related]
10. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors.
Esposito F; Tramontano E
Antivir Chem Chemother; 2014 Jan; 23(4):129-44. PubMed ID: 24150519
[TBL] [Abstract][Full Text] [Related]
11. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents.
de Soultrait VR; Lozach PY; Altmeyer R; Tarrago-Litvak L; Litvak S; Andréola ML
J Mol Biol; 2002 Nov; 324(2):195-203. PubMed ID: 12441099
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
Huang B; Kang D; Zhan P; Liu X
Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
[TBL] [Abstract][Full Text] [Related]
13. Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
Patel RV; Park SW
Bioorg Med Chem; 2015 Sep; 23(17):5247-63. PubMed ID: 26116177
[TBL] [Abstract][Full Text] [Related]
14. [Universal modular system for in vitro screening of potential inhibitors of HIV-1 replication].
Prokof'eva MM; Orlova NN; Gornostaeva AS; Shul'gin AA; Nikitenko NA; Senchenko VN; Lebedev TD; Spirin PV; Riechen K; Fehse B; Stocking C; Prasolov VS
Mol Biol (Mosk); 2014; 48(2):344-8. PubMed ID: 25850304
[TBL] [Abstract][Full Text] [Related]
15. Wikstroelide M potently inhibits HIV replication by targeting reverse transcriptase and integrase nuclear translocation.
Zhang X; Huang SZ; Gu WG; Yang LM; Chen H; Zheng CB; Zhao YX; Wan DC; Zheng YT
Chin J Nat Med; 2014 Mar; 12(3):186-93. PubMed ID: 24702804
[TBL] [Abstract][Full Text] [Related]
16. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Xue P; Lu HH; Zhu YY; Ju XL; Pannecouque C; Zheng XJ; Liu GY; Zhang XL; Gu SX
Bioorg Med Chem Lett; 2017 Apr; 27(8):1640-1643. PubMed ID: 28314598
[TBL] [Abstract][Full Text] [Related]
18. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
Santos LH; Ferreira RS; Caffarena ER
Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
[TBL] [Abstract][Full Text] [Related]
19. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
20. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase.
de Soultrait VR; Desjobert C; Tarrago-Litvak L
Curr Med Chem; 2003 Sep; 10(18):1765-78. PubMed ID: 12871103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
